Since its depletion seems sufficient to cause death in neuroblastoma, breast, ovarian, prostate and colon cancer cell lines [175,176], HDAC11 could likely function as a major regulator of solid tumors survival and progression, thus holding strong promise to serve as a druggable determinant for bladder cancer targeted therapy. Here, HDAC11 is linked to urinary bladder carcinoma.